Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2005-11-16 15:48:42 UTC |
---|
Update Date | 2023-05-30 20:56:02 UTC |
---|
HMDB ID | HMDB0000725 |
---|
Secondary Accession Numbers | - HMDB0006055
- HMDB0036576
- HMDB00725
- HMDB06055
- HMDB36576
|
---|
Metabolite Identification |
---|
Common Name | 4-Hydroxyproline |
---|
Description | 4-Hydroxyproline (hydroxyproline or Hyp) is a major component of the protein collagen. Hydroxyproline is produced by hydroxylation of the amino acid proline and is, therefore, a post-translationally modified, non-essential amino acid. Hydroxyproline and proline play key roles in collagen stability. In particular, they permit the sharp twisting of the collagen helix. Hydroxyproline is found in few proteins other than collagen. The only other mammalian protein which includes hydroxyproline is elastin. For this reason, hydroxyproline content has been used as an indicator to determine collagen and/or gelatin amount in tissue or biological samples. Increased serum and urine levels of hydroxyproline have been found in Paget's disease (PMID: 436278 ). Hydroxyproline (Hyp) content in biological fluids is used as a parameter of collagen catabolism, especially bone resorption or tissue degradation. Bedridden and elderly individuals show significantly elevated serum levels of hydroxyproline in comparison to normal, active individuals (PMID: 10706420 ). Elevated levels of urinary hydroxyproline are also indicative of muscle damage (PMID: 21988268 ). Increased reactive oxygen species (ROS) are also known to accelerate collagen degradation. Hydroxyproline levels increase in cases of depression and stress (PMID: 21483218 ). 4-Hydroxyproline is found to be associated with Alzheimer's disease, and also hydroxyprolinemia and iminoglycinuria which are both inborn errors of metabolism. 4-Hydroxyproline is also involved in metabolic disorders such as hyperprolinemia type I, hyperornithinemia with gyrate atrophy (HOGA), L-arginine:glycine amidinotransferase deficiency, creatine deficiency, and guanidinoacetate methyltransferase deficiency. A deficiency in ascorbic acid can result in impaired hydroxyproline formation (PubChem). trans-4-Hydroxy-L-proline is a biomarker for the consumption of processed meat. |
---|
Structure | O[C@H]1CN[C@@H](C1)C(O)=O InChI=1S/C5H9NO3/c7-3-1-4(5(8)9)6-2-3/h3-4,6-7H,1-2H2,(H,8,9)/t3-,4+/m1/s1 |
---|
Synonyms | Value | Source |
---|
(2S,4R)-4-Hydroxy-2-pyrrolidinecarboxylic acid | ChEBI | (2S,4R)-trans-4-Hydroxyproline | ChEBI | delta-Hydroxyproline | ChEBI | Hydroxy-L-proline | ChEBI | Hydroxyproline | ChEBI | Hyp | ChEBI | Hypro | ChEBI | L-4-Hydroxyproline | ChEBI | L-Threo-4-hydroxyproline | ChEBI | trans-Hydroxyproline | ChEBI | trans-L-Hydroxyproline | ChEBI | L-Hydroxyproline | Kegg | trans-4-Hydroxy-L-proline | Kegg | (2S,4R)-4-Hydroxy-2-pyrrolidinecarboxylate | Generator | Δ-hydroxyproline | Generator | (2S,4R)-4-Hydroxypyrrolidine-2-carboxylic acid | HMDB | (4R)-4-Hydroxy-L-proline | HMDB | 4-Hydroxy-2-pyrrolidinecarboxylic acid | HMDB | 4-Hydroxy-L-proline | HMDB | 4-L-Hydroxyproline | HMDB | Hydroxiproline | HMDB | Hydroxy-proline | HMDB | LS-Hydroxyproline | HMDB | Oxaceprol | HMDB | trans-4-Hydroxyproline | HMDB | 4 Hydroxyproline | HMDB | Oxyproline | HMDB | (-)-4-Hydroxy-2-pyrrolidinecarboxylic acid | HMDB | (2S,4R)-(-)-4-Hydroxyproline | HMDB | (2S,4R)-4-Hydroxyproline | HMDB | (R)-4-Hydroxy-(S)-proline | HMDB | (R)-4-Hydroxy-L-proline | HMDB | (S)-Hydroxyproline | HMDB | 4(R)-Hydroxy-2(S)-pyrrolidinecarboxylic acid | HMDB | 4(R)-Hydroxyproline | HMDB | 4-Hydroxy-(S)-proline | HMDB | 4-trans-Hydroxy-L-proline | HMDB | L-Hypro | HMDB | L-trans-4-Hydroxyproline | HMDB | NSC 46704 | HMDB | trans-L-4-Hydroxyproline | HMDB | 4-Hydroxyproline | HMDB |
|
---|
Chemical Formula | C5H9NO3 |
---|
Average Molecular Weight | 131.1299 |
---|
Monoisotopic Molecular Weight | 131.058243159 |
---|
IUPAC Name | (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid |
---|
Traditional Name | hypro |
---|
CAS Registry Number | 51-35-4 |
---|
SMILES | O[C@H]1CN[C@@H](C1)C(O)=O |
---|
InChI Identifier | InChI=1S/C5H9NO3/c7-3-1-4(5(8)9)6-2-3/h3-4,6-7H,1-2H2,(H,8,9)/t3-,4+/m1/s1 |
---|
InChI Key | PMMYEEVYMWASQN-DMTCNVIQSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as proline and derivatives. Proline and derivatives are compounds containing proline or a derivative thereof resulting from reaction of proline at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Proline and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Proline or derivatives
- Alpha-amino acid
- L-alpha-amino acid
- Pyrrolidine carboxylic acid
- Pyrrolidine carboxylic acid or derivatives
- Pyrrolidine
- 1,2-aminoalcohol
- Amino acid
- Secondary alcohol
- Carboxylic acid
- Secondary aliphatic amine
- Monocarboxylic acid or derivatives
- Azacycle
- Secondary amine
- Organoheterocyclic compound
- Organooxygen compound
- Organonitrogen compound
- Alcohol
- Organic nitrogen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Organic oxygen compound
- Amine
- Carbonyl group
- Aliphatic heteromonocyclic compound
|
---|
Molecular Framework | Aliphatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 274 - 275 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 361 mg/mL at 25 °C | Not Available | LogP | -3.17 | HANSCH,C ET AL. (1995) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
4-Hydroxyproline,1TMS,isomer #1 | C[Si](C)(C)O[C@H]1CN[C@H](C(=O)O)C1 | 1449.4 | Semi standard non polar | 33892256 | 4-Hydroxyproline,1TMS,isomer #2 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O)CN1 | 1354.4 | Semi standard non polar | 33892256 | 4-Hydroxyproline,1TMS,isomer #3 | C[Si](C)(C)N1C[C@H](O)C[C@H]1C(=O)O | 1432.0 | Semi standard non polar | 33892256 | 4-Hydroxyproline,2TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C)CN1 | 1442.1 | Semi standard non polar | 33892256 | 4-Hydroxyproline,2TMS,isomer #2 | C[Si](C)(C)O[C@@H]1C[C@@H](C(=O)O)N([Si](C)(C)C)C1 | 1471.9 | Semi standard non polar | 33892256 | 4-Hydroxyproline,2TMS,isomer #3 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O)CN1[Si](C)(C)C | 1442.8 | Semi standard non polar | 33892256 | 4-Hydroxyproline,3TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C)CN1[Si](C)(C)C | 1500.8 | Semi standard non polar | 33892256 | 4-Hydroxyproline,3TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C)CN1[Si](C)(C)C | 1594.0 | Standard non polar | 33892256 | 4-Hydroxyproline,3TMS,isomer #1 | C[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C)CN1[Si](C)(C)C | 1683.5 | Standard polar | 33892256 | 4-Hydroxyproline,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)O[C@H]1CN[C@H](C(=O)O)C1 | 1682.0 | Semi standard non polar | 33892256 | 4-Hydroxyproline,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O)CN1 | 1602.4 | Semi standard non polar | 33892256 | 4-Hydroxyproline,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)N1C[C@H](O)C[C@H]1C(=O)O | 1698.2 | Semi standard non polar | 33892256 | 4-Hydroxyproline,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1 | 1905.5 | Semi standard non polar | 33892256 | 4-Hydroxyproline,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@H]1C[C@@H](C(=O)O)N([Si](C)(C)C(C)(C)C)C1 | 1989.8 | Semi standard non polar | 33892256 | 4-Hydroxyproline,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O)CN1[Si](C)(C)C(C)(C)C | 1919.3 | Semi standard non polar | 33892256 | 4-Hydroxyproline,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1[Si](C)(C)C(C)(C)C | 2197.5 | Semi standard non polar | 33892256 | 4-Hydroxyproline,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1[Si](C)(C)C(C)(C)C | 2189.9 | Standard non polar | 33892256 | 4-Hydroxyproline,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)[C@@H]1C[C@@H](O[Si](C)(C)C(C)(C)C)CN1[Si](C)(C)C(C)(C)C | 2100.8 | Standard polar | 33892256 |
|
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (Non-derivatized) | splash10-000x-0950000000-5b1c397e26b28e872d20 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (Non-derivatized) | splash10-000x-0950000000-c46b5bba0f41001e3c18 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS) | splash10-00di-9530000000-00db00b15ab5341d7d64 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-MS (2 TMS) | splash10-0a4i-1900000000-c0a869abe2f1e9f8c08e | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-MS (3 TMS) | splash10-001l-1960000000-abcd0377696d2b52d815 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline EI-B (Non-derivatized) | splash10-001i-0590000000-75e03328fb2d44469057 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-EI-TOF (Non-derivatized) | splash10-000x-0950000000-c46b5bba0f41001e3c18 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-EI-TOF (Non-derivatized) | splash10-00di-9530000000-00db00b15ab5341d7d64 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-MS (Non-derivatized) | splash10-0a4i-1900000000-c0a869abe2f1e9f8c08e | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-MS (Non-derivatized) | splash10-001l-1960000000-abcd0377696d2b52d815 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-EI-TOF (Non-derivatized) | splash10-000x-0940000000-97328204c6b60a244616 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-EI-TOF (Non-derivatized) | splash10-000x-0940000000-468aeb79950a9e6dadc6 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Experimental GC-MS | GC-MS Spectrum - 4-Hydroxyproline GC-EI-TOF (Non-derivatized) | splash10-0a4i-0900000000-40c0bfa9451caacaf422 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a6r-9100000000-af92b4a861832ca4ec13 | 2016-09-22 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (2 TMS) - 70eV, Positive | splash10-02mu-9670000000-81c8390bdfa262fa9b2f | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - 4-Hydroxyproline GC-MS (TBDMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-00ku-9000000000-f5bd67093b2f30a6f62b | 2018-05-25 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline Quattro_QQQ 10V, Positive-QTOF (Annotated) | splash10-0019-9700000000-ea3ed008938a57d1263c | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline Quattro_QQQ 25V, Positive-QTOF (Annotated) | splash10-014r-9000000000-0b76109525f362b600a0 | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline Quattro_QQQ 40V, Positive-QTOF (Annotated) | splash10-014l-9000000000-477e41e40831316e68ac | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Positive-QTOF | splash10-0019-9300000000-7228a10f32d447b58ee0 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negative-QTOF | splash10-001i-0900000000-11800ca52c6e911f8313 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline LC-ESI-QTOF , negative-QTOF | splash10-001i-0900000000-11800ca52c6e911f8313 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline , negative-QTOF | splash10-001i-1900000000-b6bba00a324b6eab209f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline , negative-QTOF | splash10-001i-1900000000-ba9df49a4d967cf8851d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline LC-ESI-IT , positive-QTOF | splash10-000i-9000000000-6d125b0bb59101e9ce53 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline LC-ESI-QTOF , positive-QTOF | splash10-0019-9300000000-7228a10f32d447b58ee0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline , positive-QTOF | splash10-0019-9600000000-5bcced64c9dfeb96876f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline , positive-QTOF | splash10-0019-9600000000-b575fa8df5e2d8bb3a99 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline 40V, Positive-QTOF | splash10-014l-9000000000-c036fd15ccf6ed0c554e | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline 20V, Positive-QTOF | splash10-00kr-9000000000-8746de5249187bab94dc | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline 40V, Positive-QTOF | splash10-014i-9000000000-3f70e8e1eef8568e87ef | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline 10V, Positive-QTOF | splash10-000i-9200000000-cd32fa744ef013f5ca48 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline 10V, Positive-QTOF | splash10-000i-9200000000-3ea6a86203c48888d528 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline 40V, Positive-QTOF | splash10-02tc-9000000000-95aa07d1970d7f83f347 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - 4-Hydroxyproline 20V, Positive-QTOF | splash10-014r-9000000000-95b2178b5433b4b2db50 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxyproline 10V, Positive-QTOF | splash10-03di-3900000000-a10576d40ff1d7fc707a | 2016-09-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxyproline 20V, Positive-QTOF | splash10-02t9-9400000000-8b66308781907cdf6304 | 2016-09-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxyproline 40V, Positive-QTOF | splash10-014i-9000000000-7f9d42864b2decdbdd1d | 2016-09-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxyproline 10V, Negative-QTOF | splash10-001i-2900000000-bfc9154f784caa2e61a7 | 2016-09-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxyproline 20V, Negative-QTOF | splash10-02ar-9800000000-750b3fd4f0e1dcb8ef4c | 2016-09-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 4-Hydroxyproline 40V, Negative-QTOF | splash10-00r6-9000000000-efe39f47f6ee937ded3d | 2016-09-12 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 13C NMR Spectrum (1D, 400 MHz, H2O, experimental) | 2021-10-10 | Wishart Lab | View Spectrum | Experimental 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | 2021-10-10 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
IR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Mitochondria
- Endoplasmic reticulum
|
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Feces
- Saliva
- Urine
|
---|
Tissue Locations | - Epidermis
- Fibroblasts
- Kidney
- Liver
- Pancreas
- Placenta
- Platelet
- Prostate
- Skeletal Muscle
- Spleen
|
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Female | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Female | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | <91000 uM | Infant (0-1 year old) | Female | Normal | | details | Blood | Detected and Quantified | 16 - 53 uM | Infant (0-1 year old) | Male | Normal | | details | Blood | Detected and Quantified | 11.8 (9.9-13.7) uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 40.0 (28.0-55.0) uM | Newborn (0-30 days old) | Both | Normal | | details | Blood | Detected and Quantified | 40.0 +/- 40.0 uM | Newborn (0-30 days old) | Not Specified | Normal | | details | Blood | Detected and Quantified | 24.0 +/- 13.0 uM | Children (1-13 years old) | Male | Normal | | details | Blood | Detected and Quantified | 20.0 +/- 12.0 uM | Children (1-13 years old) | Female | Normal | | details | Blood | Detected and Quantified | 20 +/- 12 uM | Children (1 - 13 years old) | Female | Normal | | details | Blood | Detected and Quantified | 20.0 +/- 11.0 uM | Adult (>18 years old) | Male | Normal | | details | Blood | Detected and Quantified | 16.0 +/- 9.0 uM | Adult (>18 years old) | Female | Normal | | details | Blood | Detected and Quantified | 24 +/- 13 uM | Children (1 - 13 years old) | Male | Normal | | details | Blood | Detected and Quantified | 13.0 (3.0-23.0) uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 4.00-30.0 uM | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Not Specified | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Children (6 - 18 years old) | Not Specified | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Feces | Detected and Quantified | 10 +/- 10 nmol/g wet feces | Adult (>18 years old) | Both | Normal | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | 0.873 +/- 0.537 uM | Adult (>18 years old) | Female | Normal | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Not Specified | Normal | | details | Saliva | Detected and Quantified | 1.5 +/- 2.6 uM | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected and Quantified | 1.1 +/- 2.0 uM | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected and Quantified | 0.93 +/- 0.91 uM | Adult (>18 years old) | Both | Normal | | details | Saliva | Detected and Quantified | <0.25 uM | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected and Quantified | 0.432 +/- 0.431 uM | Adult (>18 years old) | Male | Normal | | details | Saliva | Detected and Quantified | <0.25 uM | Adult (>18 years old) | Male | Normal | | details | Urine | Detected and Quantified | 0.15 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 497.46 +/- 203.51 umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | 720.19 +/- 373.10 umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | 723.58 +/- 260.04 umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | <2.49 umol/mmol creatinine | Adolescent (13-18 years old) | Not Specified | Normal | | details | Urine | Detected and Quantified | 0.26-0.64 umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | Urine | Detected and Quantified | 8.12-92.19 umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | 28.41(16.96-78.82) umol/mmol creatinine | Newborn (0-30 days old) | Female | Normal | | details | Urine | Detected and Quantified | 34.65(8.07-96.55) umol/mmol creatinine | Newborn (0-30 days old) | Male | Normal | | details | Urine | Detected and Quantified | <1.70 umol/mmol creatinine | Adult (>18 years old) | Not Specified | Normal | | details | Urine | Detected and Quantified | <3.289 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | <286.82 umol/mmol creatinine | Infant (0-1 year old) | Not Specified | Normal | | details | Urine | Detected and Quantified | 1.37 +/- 0.78 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | <10.067 umol/mmol creatinine | Children (1-13 years old) | Not Specified | Normal | | details | Urine | Detected and Quantified | 0.26-0.45 umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | Urine | Detected and Quantified | 186.45 (145.78-227.11) umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | - Geigy Scientific ...
- West Cadwell, N.J...
- Basel, Switzerlan...
| details | Urine | Detected and Quantified | < 2.0 umol/mmol creatinine | Infant (6 months - <1 year old) | Both | Normal | | details | Urine | Detected and Quantified | <10.0 umol/mmol creatinine | Infant (1 - 6 months old) | Both | Normal | | details | Urine | Detected and Quantified | 7.5 +/- 2.9 umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | 2 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 6.5 (2.4-12.5) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | <5.20 umol/mmol creatinine | Children (1-13 years old) | Not Specified | Normal | | details | Urine | Detected and Quantified | 4-230 umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | 88.17 +/- 49.59 umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details | Urine | Detected and Quantified | 0 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0 umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details | Urine | Detected and Quantified | 0 umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details | Urine | Detected and Quantified | 67.94 (43.53-132.88) umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | Urine | Detected and Quantified | <143 umol/mmol creatinine | Infant (0-1 year old) | Female | Normal | | details | Urine | Detected and Quantified | 0 - 143 umol/mmol creatinine | Infant (0-1 year old) | Male | Normal | | details | Urine | Detected and Quantified | <2.15 umol/mmol creatinine | Children (1-13 years old) | Not Specified | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Blood | Detected and Quantified | 5.66 +/- 0.67 uM | Elderly (>65 years old) | Both | Alzheimer's disease | | details | Blood | Detected and Quantified | 43.8 +/- 12.5 uM | Adult (>18 years old) | Both | Hemodialysis | | details | Blood | Detected and Quantified | 27.0 +/- 14.1 uM | Adult (>18 years old) | Both | Hemodialysis | | details | Blood | Detected and Quantified | 339 uM | Infant (0-1 year old) | Male | Hydroxyprolinemia | | details | Blood | Detected and Quantified | 412000 uM | Infant (0-1 year old) | Female | Hydroxyprolinemia | | details | Blood | Detected and Quantified | 5.6 +/- 0.67 uM | Adult (>18 years old) | Both | Alzheimer's disease | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.28 +/- 0.055 uM | Adult (>18 years old) | Both | Alzheimer's disease | | details | Feces | Detected but not Quantified | Not Quantified | Children (6 - 18 years old) | Not Specified | Crohns disease | | details | Feces | Detected but not Quantified | Not Quantified | Children (6 - 18 years old) | Not Specified | Ulcerative colitis | | details | Feces | Detected but not Quantified | Not Quantified | Children (6 - 18 years old) | Not Specified | Unclassified IBD | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal Cancer | | details | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Attachment loss | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Missing teeth | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Periodontal Probing Depth | | details | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Tooth Decay | | details | Urine | Detected and Quantified | 30.862 +/- 12.249 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Eosinophilic esophagitis | | details | Urine | Detected and Quantified | 0.21 +/- 0.017 umol/mmol creatinine | Adult (>18 years old) | Both | Alzheimer's disease | | details | Urine | Detected and Quantified | 75 (50-100) umol/mmol creatinine | Children (1-13 years old) | Both | Iminoglycinuria | | details | Urine | Detected and Quantified | 0 umol/mmol creatinine | Adolescent (13-18 years old) | Both | Hyperglycinuria | | details | Urine | Detected and Quantified | 0 umol/mmol creatinine | Adult (>18 years old) | Both | Hyperglycinuria | | details | Urine | Detected and Quantified | 1957 umol/mmol creatinine | Infant (0-1 year old) | Female | Hydroxyprolinemia | | details | Urine | Detected and Quantified | 2960 umol/mmol creatinine | Infant (0-1 year old) | Male | Hydroxyprolinemia | | details | Urine | Detected and Quantified | 0-250 umol/mmol creatinine | Children (1-13 years old) | Both | Iminoglycinuria | | details | Urine | Detected and Quantified | 40-150 umol/mmol creatinine | Adult (>18 years old) | Female | Iminoglycinuria | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Alzheimer's disease |
---|
- Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG: Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids. 2007 Feb;32(2):213-24. Epub 2006 Oct 10. [PubMed:17031479 ]
| Hemodialysis |
---|
- Raj DS, Ouwendyk M, Francoeur R, Pierratos A: Plasma amino acid profile on nocturnal hemodialysis. Blood Purif. 2000;18(2):97-102. [PubMed:10838467 ]
| Colorectal cancer |
---|
- Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14. [PubMed:25105552 ]
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
| Hydroxyprolinemia |
---|
- la Marca G, Malvagia S, Pasquini E, Donati MA, Gasperini S, Procopio E, Zammarchi E: Hyperhydroxyprolinaemia: a new case diagnosed during neonatal screening with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(6):863-4. [PubMed:15723447 ]
- Baykal T, Karaaslan I, Gokcay G, Demir F, Laleli Y, Demirkol M: Hyperhydroxyprolinaemia detected in newborn screening with tandem mass spectrometry. J Inherit Metab Dis. 2004;27(6):781-2. [PubMed:15617190 ]
| Crohn's disease |
---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| Ulcerative colitis |
---|
- Kolho KL, Pessia A, Jaakkola T, de Vos WM, Velagapudi V: Faecal and Serum Metabolomics in Paediatric Inflammatory Bowel Disease. J Crohns Colitis. 2017 Mar 1;11(3):321-334. doi: 10.1093/ecco-jcc/jjw158. [PubMed:27609529 ]
| Attachment loss |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Missing teeth |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Periodontal Probing Depth |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Tooth Decay |
---|
- Liebsch C, Pitchika V, Pink C, Samietz S, Kastenmuller G, Artati A, Suhre K, Adamski J, Nauck M, Volzke H, Friedrich N, Kocher T, Holtfreter B, Pietzner M: The Saliva Metabolome in Association to Oral Health Status. J Dent Res. 2019 Jun;98(6):642-651. doi: 10.1177/0022034519842853. Epub 2019 Apr 26. [PubMed:31026179 ]
| Iminoglycinuria |
---|
- Broer S, Bailey CG, Kowalczuk S, Ng C, Vanslambrouck JM, Rodgers H, Auray-Blais C, Cavanaugh JA, Broer A, Rasko JE: Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters. J Clin Invest. 2008 Dec;118(12):3881-92. doi: 10.1172/JCI36625. Epub 2008 Nov 6. [PubMed:19033659 ]
- G.Frauendienst-Egger, Friedrich K. Trefz (2017). MetaGene: Metabolic & Genetic Information Center (MIC: http://www.metagene.de). METAGENE consortium.
| Eosinophilic esophagitis |
---|
- Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
|
|
---|
Associated OMIM IDs | |
---|
External Links |
---|
DrugBank ID | DB08847 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB013511 |
---|
KNApSAcK ID | C00001370 |
---|
Chemspider ID | 5605 |
---|
KEGG Compound ID | C01157 |
---|
BioCyc ID | 4-HYDROXY-L-PROLINE |
---|
BiGG ID | 36935 |
---|
Wikipedia Link | Hydroxyproline |
---|
METLIN ID | 257 |
---|
PubChem Compound | 5810 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 18095 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | 4HPRO_LT |
---|
MarkerDB ID | MDB00000237 |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Adams, Elijah; Goldstone, Alfred. Hydroxyproline metabolism. II. Enzymic preparation and properties of D1-pyrroline-3-hydroxy-5-carboxylic acid. Journal of Biological Chemistry (1960), 235 3492-8. |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]
- Cynober LA: Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition. 2002 Sep;18(9):761-6. [PubMed:12297216 ]
- Kelleher PC: Urinary excretion of hydroxyproline, hydroxylysine and hydroxylysine glycosides by patients with Paget's disease of bone and carcinoma with metastases in bone. Clin Chim Acta. 1979 Mar 15;92(3):373-9. [PubMed:436278 ]
- Matsuda Y, Matsumoto K, Yamada A, Ichida T, Asakura H, Komoriya Y, Nishiyama E, Nakamura T: Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. Hepatology. 1997 Jul;26(1):81-9. [PubMed:9214455 ]
- Seibel MJ, Woitge HW: Basic principles and clinical applications of biochemical markers of bone metabolism: biochemical and technical aspects. J Clin Densitom. 1999 Fall;2(3):299-321. [PubMed:10548826 ]
- Akalin FA, Sengun D, Eratalay K, Renda N, Caglayan G: Hydroxyproline and total protein levels in gingiva and gingival crevicular fluid in patients with juvenile, rapidly progressive, and adult periodontitis. J Periodontol. 1993 May;64(5):323-9. [PubMed:8515361 ]
- Akalin FA, Sengun D, Renda N, Eratalay K, Caglayan G: Hydroxyproline and total protein levels in gingiva and gingival crevicular fluid in periodontally healthy human subjects. J Nihon Univ Sch Dent. 1992 Sep;34(3):172-7. [PubMed:1287145 ]
- Lee HS, Shun CT, Chiou LL, Chen CH, Huang GT, Sheu JC: Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: Emphasis on sampling variability. J Gastroenterol Hepatol. 2005 Jul;20(7):1109-14. [PubMed:15955222 ]
- Akalin FA, Bozkurt FY, Sengun D, Renda N, Kalfa Z, Eratalay K, Velidedeoglu E: Hydroxyproline and total protein levels in gingiva from patients treated with phenytoin and cyclosporine-A. J Nihon Univ Sch Dent. 1996 Mar;38(1):21-30. [PubMed:8648408 ]
- Diaz S, Reyes MV, Zepeda A, Gonzalez GB, Lopez JM, Campino C, Croxatto HB: Norplant((R)) implants and progesterone vaginal rings do not affect maternal bone turnover and density during lactation and after weaning. Hum Reprod. 1999 Oct;14(10):2499-505. [PubMed:10527977 ]
- Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R: Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther. 2005 Oct;315(1):58-68. Epub 2005 Jun 24. [PubMed:15980055 ]
- Kondo A, Ishikawa O, Okada K, Miyachi Y, Abe S, Kuboki Y: Measurement of histidinohydroxylysinonorleucine and hydroxyproline in skin collagen by reversed-phase high-performance liquid chromatography after 9-fluorenylmethyl chloroformate labeling. Anal Biochem. 1997 Oct 15;252(2):255-9. [PubMed:9344411 ]
- Gerling B, Becker M, Waldschmidt J, Rehmann M, Schuppan D: Elevated serum aminoterminal procollagen type-III-peptide parallels collagen accumulation in rats with secondary biliary fibrosis. J Hepatol. 1996 Jul;25(1):79-84. [PubMed:8836905 ]
- Bienkowski RS: A criterion to determine whether cis-4-hydroxyproline is produced in animal tissues. Arch Biochem Biophys. 1984 Mar;229(2):455-8. [PubMed:6703705 ]
- Bellon G, Berg R, Chastang F, Malgras A, Borel JP: Separation and evaluation of the cis and trans isomers of hydroxyprolines: effect of hydrolysis on the epimerization. Anal Biochem. 1984 Feb;137(1):151-5. [PubMed:6731795 ]
- Lindblad WJ, Diegelmann RF: Quantitation of hydroxyproline isomers in acid hydrolysates by high-performance liquid chromatography. Anal Biochem. 1984 May 1;138(2):390-5. [PubMed:6742416 ]
- Shibasaki T, Mori H, Ozaki A: Enzymatic production of trans-4-hydroxy-L-proline by regio- and stereospecific hydroxylation of L-proline. Biosci Biotechnol Biochem. 2000 Apr;64(4):746-50. [PubMed:10830487 ]
- Pickersgill IF, Rapoport H: Preparation of functionalized, conformationally constrained DTPA analogues from L- or D-serine and trans-4-hydroxy-L-proline. Hydroxymethyl substituents on the central acetic acid and on the backbone. J Org Chem. 2000 Jun 30;65(13):4048-57. [PubMed:10866623 ]
- Song IK, Kang YK: Conformational preference and cis-trans isomerization of 4(R)-substituted proline residues. J Phys Chem B. 2006 Feb 2;110(4):1915-27. [PubMed:16471763 ]
- Baldwin JE, Pritchard GJ, Williamson DS: The synthesis of 4-arylsulfanyl-substituted kainoid analogues from trans-4-hydroxy-L-proline. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1927-9. [PubMed:10987419 ]
- Miskolzie M, Gera L, Stewart JM, Kotovych G: The importance of the N-terminal beta-turn in bradykinin antagonists. J Biomol Struct Dyn. 2000 Oct;18(2):249-60. [PubMed:11089646 ]
- Kofoed J, Darbre T, Reymond JL: Dual mechanism of zinc-proline catalyzed aldol reactions in water. Chem Commun (Camb). 2006 Apr 14;(14):1482-4. Epub 2006 Mar 2. [PubMed:16575434 ]
- Kuttan R, Radhakrishnan AN: Studies on bound trans-4-hydroxy-L-proline in sandal (Santalum album L.). Biochem J. 1970 Oct;119(4):651-7. [PubMed:5493503 ]
- Tasanen K, Eble JA, Aumailley M, Schumann H, Baetge J, Tu H, Bruckner P, Bruckner-Tuderman L: Collagen XVII is destabilized by a glycine substitution mutation in the cell adhesion domain Col15. J Biol Chem. 2000 Feb 4;275(5):3093-9. [PubMed:10652291 ]
- Keskiaho K, Hieta R, Sormunen R, Myllyharju J: Chlamydomonas reinhardtii has multiple prolyl 4-hydroxylases, one of which is essential for proper cell wall assembly. Plant Cell. 2007 Jan;19(1):256-69. Epub 2007 Jan 12. [PubMed:17220203 ]
- Lafranconi WM, Duhamel RC, Brendel K, Huxtable RJ: Differentiation of the cardiac and pulmonary toxicity of monocrotaline, a pyrrolizidine alkaloid. Biochem Pharmacol. 1984 Jan 15;33(2):191-7. [PubMed:6200114 ]
- Sodian R, Hoerstrup SP, Sperling JS, Martin DP, Daebritz S, Mayer JE Jr, Vacanti JP: Evaluation of biodegradable, three-dimensional matrices for tissue engineering of heart valves. ASAIO J. 2000 Jan-Feb;46(1):107-10. [PubMed:10667727 ]
- ADAMS E, GOLDSTONE A, SINGH RM, ROSSO G: SUBSTRATE ACTIVITY OF 3-HYDROXYPROLINE ISOMERS FOR ENZYMES ACTIVE WITH 4-HYDROXYPROLINE. Biochim Biophys Acta. 1964 Jul 8;89:164-6. [PubMed:14212996 ]
- Last JA, Reiser KM, Tyler WS, Rucker RB: Long-term consequences of exposure to ozone. I. Lung collagen content. Toxicol Appl Pharmacol. 1984 Jan;72(1):111-8. [PubMed:6710477 ]
- Koike K, Li Y, Seo M, Sakurada I, Tezuka K, Uchikura K: Free 4-hydroxyproline content in serum of bedridden aged people is elevated due to fracture. Biol Pharm Bull. 2000 Jan;23(1):101-3. [PubMed:10706420 ]
- Burjanadze TV: New analysis of the phylogenetic change of collagen thermostability. Biopolymers. 2000 May;53(6):523-8. [PubMed:10775067 ]
- Dixon IM, Hao J, Reid NL, Roth JC: Effect of chronic AT(1) receptor blockade on cardiac Smad overexpression in hereditary cardiomyopathic hamsters. Cardiovasc Res. 2000 May;46(2):286-97. [PubMed:10773233 ]
- Turpeenniemi-Hujanen T, Myllyla R: Concomitant hydroxylation of proline and lysine residues in collagen using purified enzymes in vitro. Biochim Biophys Acta. 1984 Jul 16;800(1):59-65. [PubMed:6331520 ]
- Nogueira Ade C, Vale RG, Gomes AL, Dantas EH: The effect of muscle actions on the level of connective tissue damage. Res Sports Med. 2011 Oct;19(4):259-70. doi: 10.1080/15438627.2011.608046. [PubMed:21988268 ]
- Lee KW, Kim SJ, Park JB, Lee KJ: Relationship between depression anxiety stress scale (DASS) and urinary hydroxyproline and proline concentrations in hospital workers. J Prev Med Public Health. 2011 Jan;44(1):9-13. doi: 10.3961/jpmph.2011.44.1.9. [PubMed:21483218 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
- (). Yannai, Shmuel. (2004) Dictionary of food compounds with CD-ROM: Additives, flavors, and ingredients. Boca Raton: Chapman & Hall/CRC.. .
|
---|